Dr. Noor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 CAMBRIDGE parkway
Cambridge, MA 02142- Is this information wrong?
Summary
- Physician scientist, chief medical officer in biotech. 20+ Years in clinical development of novel therapeutics in multiple diseas areas and indications including metabolic cardiovascular inflammation and general medicine.
Education & Training
- Vanderbilt University School of MedicineMS, 2001 - 2002
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
- Scripps Clinic/Scripps Green HospitalResidency, Internal Medicine, 1994 - 1997
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1994
- The University of ChicagoBA, 1986 - 1990
Certifications & Licensure
- CA State Medical License 1995 - 2025
- MA State Medical License 2013 - 2024
- PA State Medical License 2004 - 2016
- GA State Medical License 2002 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Start of enrollment: 2023 Jan 06
Publications & Presentations
PubMed
- 4 citationsRetrospective analysis of inferior vena cava collapsibility with point of care ultrasound and urine sodium and FENa in patients with early stage acute kidney injury.Faizan Babar, Gurkeerat Singh, Mustafa Noor, Bruce F. Sabath> ;Journal of Community Hospital Internal Medicine Perspectives. 2017 Oct 18
- 4 citationsSplenic infarct in a patient with Infectious Mononucleosis: a rare presentation.Mustafa Noor, Maryam Sadough, Stephanie Chan, Gurkeerat Singh> ;Journal of Community Hospital Internal Medicine Perspectives. 2017 Sep 19
- 65 citationsThe Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical ImplicationsOliver P. Flint, Mustafa A. Noor, Paul W. Hruz, Phillip B. Hylemon, Kevin E. Yarasheski, Donald P. Kotler, Rex A. Parker, Aouatef Bellamine> ;Toxicologic Pathology. 2009 Jan 1
- Join now to see all
Journal Articles
- The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implicationsNoor MA, Current HIV/AIDS Report, 1/1/2007
- The Effects of Atazanavir/ritonavir and Lopinavir/ritonavir on Insulin Sensitivity: Demonstrable Differences in vitro and ClinicallyNoor MA, Flint OP, Maa J and Parker RA, AIDS, 1/1/2006
- Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease InhibitorsParker RA, Flint OP, Mulvey R, Elosua C, Wang F, Fenderson W, Yang WP and Noor MA, Molecular Pharmacology, 1/1/2005
- Join now to see all
Abstracts/Posters
- The Effect of atazanavir vs. lopinavir/ritonavir on insulin-stimulated glucose disposal rate in healthy subjectsNoor MA, Grasela D, Parker R, Chaudhari U, Uderman H, Currie A, Agarwala S, Grunfeld C, Giordano M, Hodder S, Fiedorek F and O’Mara E, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 1/1/2004
- Indinavir increases hepatic glucose production in healthy HIV-negative menNoor MA, Park S, Lee GA, Schwarz JM, Lee J, Wen M, Lo JC, Mulligan K, Schambelan M and Grunfeld C, 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Antiviral Therapy, Paris, France, 1/1/2003
- HIV protease inhibitors and the Hepatic MetabolomeFlint OP, Elosua C, Parker RA, Hamilton CM., Noor MA, 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO
- Join now to see all
Lectures
- Metabolic Mechanism of Protease Inhibitor-Induced Insulin Resistance and DyslipidemiaBrown University Miriam Hospital, Providence, RI - 1/1/2005
- Metabolic Profile of HIV Protease Inhibitors – Mechanisms and InsightsMultiple locations - 1/1/2005
- Metabolic Profile of HIV Protease Inhibitors – An Endocrinologist’s PerspectiveSt. Vincent’s Hospital, New York, NY - 1/1/2005
- Join now to see all
External Links
- Olatec Therapeutics http://Olatec.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: